Latest News

Moderna Profit Falls Amid Charges for Unused Covid-19 Vaccines


Vaccine maker’s quarterly profit falls on charges tied to expired doses, changes to purchase agreements

Moderna is the latest drugmaker to post quarterly sales gains due to continued demand for its Covid-19 products.Photo: Rogelio V. Solis/Associated Press

Moderna sales rose 9% in the second quarter as demand for its Covid-19 vaccine remained strong.

The Cambridge, Mass.-based biotechnology company’s revenue came in at $4.75 billion in the period ended June 30, topping Wall Street analyst expectations, driven almost entirely by sales of its messenger RNA-based vaccine, branded as Spikevax.

Most Popular news

Most Popular opinion

Recommended Videos

Seeking at Least 13% Dividend Yield? Analysts Suggest 2 Dividend Stocks to Buy

Previous article

Michael Saylor Bet Billions on Bitcoin and Lost

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News